<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Acura Pharmaceuticals Inc.</title>
	<atom:link href="http://www.stockbloghub.com/tag/acura-pharmaceuticals-inc/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Sun, 20 May 2012 20:27:31 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(PFE) Pfizer and Acura Pharmaceuticals Win FDA Approval for Oxecta</title>
		<link>http://www.stockbloghub.com/2011/06/23/pfe-pfizer-and-acura-pharmaceuticals-win-fda-approval-for-oxecta/77271</link>
		<comments>http://www.stockbloghub.com/2011/06/23/pfe-pfizer-and-acura-pharmaceuticals-win-fda-approval-for-oxecta/77271#comments</comments>
		<pubDate>Thu, 23 Jun 2011 20:12:32 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACUR]]></category>
		<category><![CDATA[Acura Pharmaceuticals Inc.]]></category>
		<category><![CDATA[DRRX]]></category>
		<category><![CDATA[Durect Corporation]]></category>
		<category><![CDATA[Ingersoll-Rand Company Limited]]></category>
		<category><![CDATA[IR]]></category>
		<category><![CDATA[Pain Therapeutics Inc.]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PTIE]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77271</guid>
		<description><![CDATA[Pfizer Inc. (PFE) and partner Acura Pharmaceuticals Inc. (ACUR) recently received US Food and Drug Administration (FDA) approval for their pain treatment, Oxecta (oxycodone). Oxecta (formerly known as Acurox) gained approval for the management of acute and chronic moderate to severe pain where the use of an opioid analgesic is appropriate. Oxecta became a part of Pfizer’s portfolio following its acquisition of King Pharma earlier this year. Oxecta has been developed under an agreement for the licensing, development, and commercialization of immediate release (IR) pain medicines utilizing Acura&#8217;s Aversion (abuse-deterrent) technology. The abuse-deterrent technology has been designed to discourage opioid abuse and misuse through common ways of tampering. Oxecta’s approval triggers a $20 million milestone payment to Acura from Pfizer. Remoxy Action Date Round the Corner Pfizer has another important ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/23/pfe-pfizer-and-acura-pharmaceuticals-win-fda-approval-for-oxecta/77271/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AFAM) Company News for June 21, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/06/21/afam-company-news-for-june-21-2011-corporate-summary/76924</link>
		<comments>http://www.stockbloghub.com/2011/06/21/afam-company-news-for-june-21-2011-corporate-summary/76924#comments</comments>
		<pubDate>Tue, 21 Jun 2011 15:28:06 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Home Health Care]]></category>
		<category><![CDATA[ACUR]]></category>
		<category><![CDATA[Acura Pharmaceuticals Inc.]]></category>
		<category><![CDATA[AFAM]]></category>
		<category><![CDATA[Agrium Inc.]]></category>
		<category><![CDATA[AGU]]></category>
		<category><![CDATA[Almost Family Inc.]]></category>
		<category><![CDATA[ASH]]></category>
		<category><![CDATA[Ashland Inc.]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Carpenter Technology Corporation]]></category>
		<category><![CDATA[CRS]]></category>
		<category><![CDATA[DB]]></category>
		<category><![CDATA[Deutsche Bank AG]]></category>
		<category><![CDATA[Goldman Sachs Group]]></category>
		<category><![CDATA[GS]]></category>
		<category><![CDATA[Harbin Electric Inc.]]></category>
		<category><![CDATA[HRBN]]></category>
		<category><![CDATA[PETM]]></category>
		<category><![CDATA[Petsmart Inc.]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PNC]]></category>
		<category><![CDATA[PNC Financial Services Group Inc]]></category>
		<category><![CDATA[Skyworks Solutions Inc.]]></category>
		<category><![CDATA[SWKS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76924</guid>
		<description><![CDATA[•    Manufacturer and distributors of stainless steel and titanium products, Carpenter Technology (NYSE:CRS)  has concluded a merger agreement with Latrobe Specialty Metals as per which the former will acquire the latter in a deal worth around $558 million •    Shares of PNC Financial Services (NYSE:PNC) fell marginally, by 1.96% after the company announced it was acquiring the U.S. retail banking operations of the Royal Bank of Canada for $3.45 billion •    Chinese electric-motor manufacturer Harbin Electric (NASDAQ:HRBN) has entered into a definitive agreement as per which it will be acquired by a company owned by Chairman and Chief Executive Tianfu Yang for $744 million •    Share prices of Agrium Inc. (NYSE:AGU) jumped 4.05% to close at $82.98 after the company increased its outlook for second quarter earnings. Agrium said strong ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/21/afam-company-news-for-june-21-2011-corporate-summary/76924/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PFE) Pfizer Extends King Pharmaceuticals Stock Tender Offer</title>
		<link>http://www.stockbloghub.com/2011/01/24/pfe-pfizer-extends-king-pharmaceuticals-stock-tender-offer/65660</link>
		<comments>http://www.stockbloghub.com/2011/01/24/pfe-pfizer-extends-king-pharmaceuticals-stock-tender-offer/65660#comments</comments>
		<pubDate>Tue, 25 Jan 2011 02:49:16 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACUR]]></category>
		<category><![CDATA[Acura Pharmaceuticals Inc.]]></category>
		<category><![CDATA[DRRX]]></category>
		<category><![CDATA[Durect Corporation]]></category>
		<category><![CDATA[Ingersoll-Rand Company Limited]]></category>
		<category><![CDATA[IR]]></category>
		<category><![CDATA[KG]]></category>
		<category><![CDATA[King Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Pain Therapeutics Inc.]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PTIE]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=65660</guid>
		<description><![CDATA[Pfizer Inc. (PFE) recently announced that it has extended the expiration date of its tender offer for all outstanding shares of King Pharmaceuticals, Inc. (KG) by 7 days. The tender offer is now set to expire on January 28, 2011. As of January 20, 2011, about 46.6% of King Pharma’s outstanding shares were validly tendered. Acquisition Deal Announced in October 2010 Pfizer had initially announced its intention to acquire King Pharma on October 12, 2010 for $14.25 per share. The offer price represents a 40% premium to King Pharma’s closing price on Oct 11, 2010. At the time of announcing the acquisition, Pfizer had said that it expects the deal to boost its 2011 and 2012 earnings by 2 cents annually and 2013 – 2015 earnings by 3-4 cents annually. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/01/24/pfe-pfizer-extends-king-pharmaceuticals-stock-tender-offer/65660/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(KG) King Pharmaceuticals Files New Drug Application for Pain Drug</title>
		<link>http://www.stockbloghub.com/2010/12/27/kg-king-pharmaceuticals-files-new-drug-application-for-pain-drug/63195</link>
		<comments>http://www.stockbloghub.com/2010/12/27/kg-king-pharmaceuticals-files-new-drug-application-for-pain-drug/63195#comments</comments>
		<pubDate>Tue, 28 Dec 2010 00:02:30 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACUR]]></category>
		<category><![CDATA[Acura Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Ingersoll-Rand Company Limited]]></category>
		<category><![CDATA[IR]]></category>
		<category><![CDATA[KG]]></category>
		<category><![CDATA[King Pharmaceuticals Inc.]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=63195</guid>
		<description><![CDATA[King Pharmaceuticals, Inc. (KG) and partner Acura Pharmaceuticals, Inc. (ACUR) recently announced the submission of a new drug application (NDA) for their opioid candidate, Acurox. The companies are seeking US Food and Drug Administration (FDA) approval for the use of Acurox (without niacin) for providing relief from moderate to severe pain. Acurox has been developed using Acura’s Aversion technology. King Pharma is seeking priority review for the candidate. King Pharma and Acura had also submitted a new drug application seeking approval for Acurox (with niacin) for which the companies received a Complete Response Letter (CRL) on June 30, 2009. Based on discussions with the FDA, King Pharma and Acura submitted the NDA to an FDA advisory panel. However, earlier this year, the FDA panel voted that they did not have sufficient ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/12/27/kg-king-pharmaceuticals-files-new-drug-application-for-pain-drug/63195/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(KG) King Pharmaceuticals and Acura Pharmaceuticals Files New Drug Application for Pain Drug</title>
		<link>http://www.stockbloghub.com/2010/12/27/kg-king-pharmaceuticals-and-acura-pharmaceuticals-files-new-drug-application-for-pain-drug/63265</link>
		<comments>http://www.stockbloghub.com/2010/12/27/kg-king-pharmaceuticals-and-acura-pharmaceuticals-files-new-drug-application-for-pain-drug/63265#comments</comments>
		<pubDate>Mon, 27 Dec 2010 16:15:45 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACUR]]></category>
		<category><![CDATA[Acura Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Ingersoll-Rand Company Limited]]></category>
		<category><![CDATA[IR]]></category>
		<category><![CDATA[KG]]></category>
		<category><![CDATA[King Pharmaceuticals Inc.]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=63265</guid>
		<description><![CDATA[King Pharmaceuticals, Inc. (KG) and partner Acura Pharmaceuticals, Inc. (ACUR) recently announced the submission of a new drug application (NDA) for their opioid candidate, Acurox. The companies are seeking US Food and Drug Administration (FDA) approval for the use of Acurox (without niacin) for providing relief from moderate to severe pain. Acurox has been developed using Acura’s Aversion technology. King Pharma is seeking priority review for the candidate. King Pharma and Acura had also submitted a new drug application seeking approval for Acurox (with niacin) for which the companies received a Complete Response Letter (CRL) on June 30, 2009. Based on discussions with the FDA, King Pharma and Acura submitted the NDA to an FDA advisory panel. However, earlier this year, the FDA panel voted that they did not have sufficient ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/12/27/kg-king-pharmaceuticals-and-acura-pharmaceuticals-files-new-drug-application-for-pain-drug/63265/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(KG) King Pharmaceuticals Announces FDA Panel Votes Against Acurox</title>
		<link>http://www.stockbloghub.com/2010/04/27/kg-king-pharmaceuticals-announces-fda-panel-votes-against-acurox/35018</link>
		<comments>http://www.stockbloghub.com/2010/04/27/kg-king-pharmaceuticals-announces-fda-panel-votes-against-acurox/35018#comments</comments>
		<pubDate>Tue, 27 Apr 2010 17:40:39 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACUR]]></category>
		<category><![CDATA[Acura Pharmaceuticals Inc.]]></category>
		<category><![CDATA[KG]]></category>
		<category><![CDATA[King Pharmaceuticals Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=35018</guid>
		<description><![CDATA[The US Food and Drug Administration’s (FDA) advisory panel recently withheld the approval for opioid candidate, Acurox, used in treating moderate to severe pain. Acurox is an orally administered tablet containing oxycodone HCl as an active analgesic ingredient, niacin as an active ingredient in subtherapeutic amounts, and a unique combination of other ingredients. The candidate has been developed as per King Pharmaceuticals, Inc.’s (KG) agreement with Acura Pharmaceuticals, Inc. (ACUR) for the licensing, development, and commercialization of immediate release (IR) pain medicines utilizing Acura&#8217;s Aversion (abuse-deterrent) technology. The advisory panel’s opposition to the approval does not come as a surprise. Earlier in June 2009, King and Acura had received a complete response letter from the FDA regarding the New Drug Application (NDA) for Acurox. At that time, the FDA had ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/27/kg-king-pharmaceuticals-announces-fda-panel-votes-against-acurox/35018/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(KR) King Pharmaceuticals Moves Pain Candidate</title>
		<link>http://www.stockbloghub.com/2010/04/08/kr-king-pharmaceuticals-moves-pain-candidate/33263</link>
		<comments>http://www.stockbloghub.com/2010/04/08/kr-king-pharmaceuticals-moves-pain-candidate/33263#comments</comments>
		<pubDate>Thu, 08 Apr 2010 23:39:01 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Grocery Stores]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ACUR]]></category>
		<category><![CDATA[Acura Pharmaceuticals Inc.]]></category>
		<category><![CDATA[DRRX]]></category>
		<category><![CDATA[Durect Corporation]]></category>
		<category><![CDATA[KR]]></category>
		<category><![CDATA[Kroger Company]]></category>
		<category><![CDATA[Pain Therapeutics Inc.]]></category>
		<category><![CDATA[PTIE]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=33263</guid>
		<description><![CDATA[King Pharmaceuticals (KR) recently moved pain candidate, Eladur, which has been in-licensed from Durect Corporation (DRRX) into a phase IIb study. Eladur, a transdermal drug patch, is intended to provide continuous delivery of bupivacaine for up to 3 days from a single application, as compared to a wearing time limited to 12 hours with currently available lidocaine patches. The candidate has been developed using Durect’s proprietary TRANSDUR transdermal technology. The phase IIb 12-week, randomized, double-blind, placebo-controlled trial will study the efficacy and safety of Eladur in patients suffering from chronic low back pain. About 260 patients will participate in this study. Eladur became a part of King’s pipeline portfolio following its December 2008 acquisition of Alpharma. In addition to Eladur, King has several pain candidates in its pipeline including Remoxy ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/08/kr-king-pharmaceuticals-moves-pain-candidate/33263/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(KG) King Pharmaceuticals and Acura Pharmaceuticals Learn FDA to Review Acurox</title>
		<link>http://www.stockbloghub.com/2010/03/18/kg-king-pharmaceuticals-and-acura-pharmaceuticals-learn-fda-to-review-acurox/31216</link>
		<comments>http://www.stockbloghub.com/2010/03/18/kg-king-pharmaceuticals-and-acura-pharmaceuticals-learn-fda-to-review-acurox/31216#comments</comments>
		<pubDate>Thu, 18 Mar 2010 20:36:28 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACUR]]></category>
		<category><![CDATA[Acura Pharmaceuticals Inc.]]></category>
		<category><![CDATA[KG]]></category>
		<category><![CDATA[King Pharmaceuticals Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=31216</guid>
		<description><![CDATA[King Pharmaceuticals, Inc. (KG) and Acura Pharmaceuticals, Inc. (ACUR) recently announced that the FDA has established a date for an advisory committee meeting which will discuss the new drug application for Acurox. The committee will also discuss the results of studies evaluating the addition of niacin for the purpose of reducing the misuse of oxycodone. The meeting, scheduled to take place on April 22, will be a joint meeting of the Anesthetic and Life Support Drugs and the Drug Safety and Risk Management Advisory Committees. Acurox is an orally administered tablet containing oxycodone HCl as an active analgesic ingredient, niacin as an active ingredient in subtherapeutic amounts, and a unique combination of other ingredients. The drug has been developed under King’s agreement with Acura Pharmaceuticals for the licensing, development, and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/18/kg-king-pharmaceuticals-and-acura-pharmaceuticals-learn-fda-to-review-acurox/31216/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(KG) King Pharmaceuticals and Acura Pharmaceuticals Report Positive Data on Acurox Study</title>
		<link>http://www.stockbloghub.com/2010/03/09/kg-king-pharmaceuticals-and-acura-pharmaceuticals-report-positive-data-on-acurox-study/30181</link>
		<comments>http://www.stockbloghub.com/2010/03/09/kg-king-pharmaceuticals-and-acura-pharmaceuticals-report-positive-data-on-acurox-study/30181#comments</comments>
		<pubDate>Tue, 09 Mar 2010 22:41:07 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACUR]]></category>
		<category><![CDATA[Acura Pharmaceuticals Inc.]]></category>
		<category><![CDATA[KG]]></category>
		<category><![CDATA[King Pharmaceuticals Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=30181</guid>
		<description><![CDATA[King Pharmaceuticals, Inc. (KG) and Acura Pharmaceuticals, Inc. (ACUR) recently presented positive top-line data on opioid candidate Acurox from a study that was conducted to assess the relative abuse potential of the drug. Results from Study AP-ADF-114 (A Randomized, Double-Blind, Placebo- and Active-Controlled Study to Assess the Relative Abuse Potential of Acurox Tablets in Non-Dependent Recreational Opioid Users) showed that Acurox was significantly disliked compared to oxycodone HCl tablets alone when excess doses are swallowed. All five co-primary endpoints of the study were achieved. Acurox is an orally administered tablet containing oxycodone HCl as an active analgesic ingredient, niacin as an active ingredient in subtherapeutic amounts, and a unique combination of other ingredients. The drug has been developed under King’s agreement with Acura Pharmaceuticals for the licensing, development, and commercialization ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/09/kg-king-pharmaceuticals-and-acura-pharmaceuticals-report-positive-data-on-acurox-study/30181/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(KG) King Pharmaceuticals Launches Embeda for Around-The-Clock Pain Relief</title>
		<link>http://www.stockbloghub.com/2009/09/24/kg-king-pharmaceuticals-launches-embeda-for-around-the-clock-pain-relief/16013</link>
		<comments>http://www.stockbloghub.com/2009/09/24/kg-king-pharmaceuticals-launches-embeda-for-around-the-clock-pain-relief/16013#comments</comments>
		<pubDate>Thu, 24 Sep 2009 19:39:12 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Featured]]></category>
		<category><![CDATA[ACUR]]></category>
		<category><![CDATA[Acura Pharmaceuticals Inc.]]></category>
		<category><![CDATA[DRRX]]></category>
		<category><![CDATA[Durect Corp.]]></category>
		<category><![CDATA[KG]]></category>
		<category><![CDATA[King Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Pain Therapeutics Inc.]]></category>
		<category><![CDATA[PTIE]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=16013</guid>
		<description><![CDATA[Earlier this week, King Pharmaceuticals, Inc. (KG) announced the launch of Embeda, which recently received U.S. Food and Drug Administration (FDA) approval for the management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time. Embeda, which is the first FDA-approved long-acting opioid designed to reduce drug liking and euphoria when tampered with by crushing or chewing, will be available in six dosage strengths. As per the requirement of the FDA, the company has also implemented a Risk Evaluation and Mitigation Strategy (REMS) under which patients and providers will be informed about the potential for abuse, misuse, overdose, and addiction of Embeda and about the safe use of the opioid. The approval and launch of Embeda is a significant milestone for ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/24/kg-king-pharmaceuticals-launches-embeda-for-around-the-clock-pain-relief/16013/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(KG) FDA Advisory Panel to Review Acurox</title>
		<link>http://www.stockbloghub.com/2009/09/04/kg-fda-advisory-panel-to-review-acurox/14484</link>
		<comments>http://www.stockbloghub.com/2009/09/04/kg-fda-advisory-panel-to-review-acurox/14484#comments</comments>
		<pubDate>Fri, 04 Sep 2009 22:54:16 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACUR]]></category>
		<category><![CDATA[Acura Pharmaceuticals Inc.]]></category>
		<category><![CDATA[KG]]></category>
		<category><![CDATA[King Pharmaceuticals]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14484</guid>
		<description><![CDATA[King Pharmaceuticals, Inc. (KG) and Acura Pharmaceuticals, Inc. (ACUR) recently met with the U.S. Food and Drug Administration (FDA) to discuss the agency’s response to the New Drug Application (NDA) for Acurox (oxycodone HCl and niacin). The companies and the agency agreed that the NDA should be reviewed by an FDA advisory committee. The agency has not asked the companies to conduct additional clinical trials. Acurox is an orally administered immediate release tablet containing oxycodone HCl as an active analgesic ingredient, niacin as an active ingredient in subtherapeutic amounts, and a unique combination of other ingredients. King and Acura are looking to gain approval of Acurox for the relief of moderate-to-severe pain. Acurox is also designed to discourage some common methods of misuse and abuse. In its complete response letter, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/04/kg-fda-advisory-panel-to-review-acurox/14484/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

